# Genotype-Aware Biomarker Intelligence: A Multi-Collection RAG Architecture for Precision Health on NVIDIA DGX Spark

**Author:** Adam Jones
**Date:** March 2026
**Version:** 1.0.0
**License:** Apache 2.0

Part of the HCLS AI Factory -- an end-to-end precision medicine platform.
https://github.com/ajones1923/hcls-ai-factory

---

## Abstract

Clinical laboratory medicine relies on population-derived reference ranges to classify biomarker values as normal or abnormal. These ranges represent statistical averages across demographically diverse cohorts and ignore the genetic variation that shapes individual biochemistry. A patient carrying MTHFR C677T homozygous variant may exhibit a homocysteine level of 14 umol/L -- within the standard reference range of 5-15 umol/L -- yet clinically elevated relative to the genotype-adjusted threshold of 10 umol/L for TT carriers. This interpretive gap between population norms and individual biology represents a fundamental limitation of current clinical laboratory practice.

This paper presents the Precision Biomarker Intelligence Agent, an open-source system that combines 13 biomarker-specific Milvus vector collections plus one read-only genomic evidence collection (14 total) with four computational analysis modules -- biological age estimation (PhenoAge and GrimAge surrogate), pre-symptomatic disease trajectory prediction across 9 disease categories, pharmacogenomic mapping for 14 CPIC-guided pharmacogenes, and genotype-adjusted reference range calculation -- to deliver personalized biomarker interpretation. The system employs 384-dimensional BAAI/bge-small-en-v1.5 embeddings under IVF_FLAT indexing with cosine similarity. A multi-domain knowledge graph spanning 7 disease domains, 14 pharmacogenes, PhenoAge clock biomarkers, and 8 cross-modal links augments vector retrieval with structured clinical context. Parallel search via ThreadPoolExecutor across all 14 collections delivers cross-functional answers with evidence citations. The system includes critical value detection, cross-biomarker discordance analysis, longitudinal tracking, and ancestry-aware adjustments. A 12-section clinical report generator produces comprehensive patient reports exportable to Markdown, PDF (ReportLab), and FHIR R4 DiagnosticReport bundles. Comprising approximately 29,000 lines of Python across 57 files with 709 tests across 18 test files, the agent runs on a single NVIDIA DGX Spark ($4,699) and is released under the Apache 2.0 license. We demonstrate that a carefully designed multi-collection RAG architecture, augmented with deterministic computational engines, can transform raw biomarker and genetic data into actionable precision health intelligence that accounts for the genetic individuality that population reference ranges ignore.

---

## 1. Introduction

### 1.1 The Problem: One-Size-Fits-All Laboratory Medicine

Every day, millions of laboratory results are reported to clinicians using reference ranges derived from population studies. These ranges -- typically defined as the central 95th percentile of a healthy reference population -- serve as the primary decision boundary for clinical action. A fasting glucose of 99 mg/dL is reported as "normal" regardless of whether the patient carries zero, one, or two TCF7L2 risk alleles, despite robust evidence that TCF7L2 rs7903146 TT carriers progress to diabetes at lower glycemic thresholds than non-carriers (Grant et al. 2006, PMID:16415884; Florez et al. 2012, PMID:22399527).

This population-averaging approach creates three categories of clinical error:

1. **False reassurance.** Patients with genetic predispositions that lower the clinically meaningful threshold are told their results are "normal" when early intervention is warranted. A PNPLA3 I148M GG carrier with an ALT of 34 U/L falls within the standard reference range but exceeds the genotype-adjusted upper limit of 35 U/L for homozygous carriers (Romeo et al. 2008, PMID:18820127).

2. **Missed trajectories.** Without longitudinal analysis contextualized by genotype, pre-symptomatic disease progression is invisible until values cross population thresholds. A patient's fasting glucose rising from 85 to 98 mg/dL over three years remains "normal" by conventional criteria, yet this trajectory in a TCF7L2 TT carrier represents clinically significant beta-cell deterioration.

3. **Pharmacogenomic blindness.** Standard lab reports provide no integration with pharmacogenomic data. A CYP2D6 poor metabolizer prescribed codeine receives a lab result showing a normal CRP level, but the report cannot flag that the patient's genotype renders codeine therapeutically ineffective -- a safety-critical omission.

### 1.2 Our Contribution

The Precision Biomarker Intelligence Agent addresses these limitations through five contributions:

1. A **multi-collection RAG architecture** with 13 biomarker-specific vector collections and 1 read-only genomic evidence collection, searched in parallel with configurable weighted scoring, delivering cross-domain evidence synthesis for precision biomarker queries.

2. A **genotype-aware interpretation engine** that adjusts reference ranges for individual genetic variants including MTHFR, APOE, PNPLA3, HFE, DIO2, VDR, FADS1, TCF7L2, and others, replacing population averages with genotype-stratified thresholds grounded in published pharmacogenomic and genetic epidemiology literature.

3. A **biological age estimation module** implementing PhenoAge (Levine et al. 2018) and GrimAge surrogate (Lu et al. 2019) from 9 routine blood biomarkers, providing patients and clinicians with an integrated aging metric beyond chronological age.

4. A **pre-symptomatic disease trajectory engine** that detects early disease progression across 9 categories using genotype-stratified biomarker thresholds, enabling intervention years before conventional diagnostic criteria are met.

5. A **complete open-source implementation** comprising 709 tests across 18 test files, 19+ API endpoints across 3 routers, and 8 UI tabs, released under Apache 2.0 and deployable on a single NVIDIA DGX Spark ($4,699).

---

## 2. Background

### 2.1 Biomarkers in Precision Medicine

The term "biomarker" encompasses any measurable indicator of biological state, from simple serum chemistry panels to complex proteomic signatures. The Biomarkers, EndpointS and other Tools (BEST) framework, developed jointly by the FDA and NIH, defines seven biomarker categories: susceptibility/risk, diagnostic, monitoring, prognostic, predictive, pharmacodynamic/response, and safety. The clinical laboratory produces the most frequently used biomarkers in medicine: complete blood counts, metabolic panels, lipid profiles, thyroid function tests, and inflammatory markers. These tests generate billions of results annually, yet their interpretation has remained largely unchanged since the establishment of reference range methodology in the mid-20th century.

The precision medicine revolution -- catalyzed by the completion of the Human Genome Project and the subsequent collapse in sequencing costs from $100 million per genome in 2001 to under $200 in 2025 -- has demonstrated that genetic variation profoundly influences biomarker levels and their clinical significance. Whole genome sequencing is increasingly available in clinical settings, creating a growing population of patients with genotype data that could inform biomarker interpretation but currently does not. Three domains of genetic influence are particularly well-characterized:

- **Pharmacogenomics.** Genetic variation in drug-metabolizing enzymes (CYP2D6, CYP2C19, CYP2C9, CYP3A5) and drug targets (VKORC1, SLCO1B1) determines drug efficacy and toxicity. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published Level 1A guidelines for over 400 gene-drug pairs.

- **Disease susceptibility.** Common variants in genes such as TCF7L2 (diabetes), APOE (cardiovascular and neurodegenerative disease), PNPLA3 (liver disease), and HFE (iron metabolism) modify the biomarker thresholds at which disease progresses.

- **Nutritional genomics.** Variants in MTHFR, FADS1, VDR, BCMO1, and FUT2 alter nutrient metabolism, creating genotype-specific requirements for folate, omega-3 fatty acids, vitamin D, vitamin A, and vitamin B12 respectively.

### 2.2 Pharmacogenomics: From Genotype to Drug Dosing

Pharmacogenomics translates genetic variation in drug-metabolizing enzymes and transporters into actionable prescribing guidance. The field has matured substantially since the first CPIC guideline was published in 2011, with guidelines now covering the majority of high-impact gene-drug interactions encountered in clinical practice. The standard workflow involves three steps: (1) identify the patient's star allele diplotype for a pharmacogene, (2) translate the diplotype to a metabolizer phenotype (poor, intermediate, normal/extensive, rapid, ultrarapid), and (3) apply CPIC-recommended dosing adjustments based on the phenotype.

Despite robust evidence and guideline availability, pharmacogenomic information is rarely integrated with routine laboratory results. A patient receiving warfarin may have CYP2C9 and VKORC1 genotyping performed by a specialty pharmacogenomics laboratory, while their INR monitoring occurs through a separate clinical laboratory -- with no system connecting the two data streams. Studies estimate that fewer than 5% of patients with available pharmacogenomic data have it systematically integrated into their laboratory result interpretation. This disconnect persists not because of scientific uncertainty but because of systems-level fragmentation between genomic and clinical laboratory data.

### 2.3 Biological Aging: Beyond Chronological Age

The recognition that biological age diverges from chronological age has driven development of multiple aging clocks. PhenoAge (Levine et al. 2018, PMID:29676998) uses 9 routine clinical biomarkers -- albumin, creatinine, glucose, C-reactive protein (CRP), lymphocyte percentage, mean corpuscular volume (MCV), red cell distribution width (RDW), alkaline phosphatase, and white blood cell count -- to estimate biological age based on Gompertz mortality modeling from NHANES III data. GrimAge (Lu et al. 2019, PMID:30669119) incorporates DNA methylation surrogates of plasma proteins (GDF-15, cystatin C, leptin, PAI-1, TIMP-1, adrenomedullin) and smoking pack-years. Both clocks predict morbidity and mortality independently of chronological age.

The clinical utility of these clocks lies in their ability to quantify accelerated or decelerated aging from routine laboratory data, providing an integrative metric that no single biomarker captures alone. A patient with a chronological age of 45 but a PhenoAge of 52 exhibits biological aging acceleration of +7 years, indicating elevated mortality risk and potential benefit from targeted interventions addressing the top contributing biomarkers.

---

## 3. System Architecture

### 3.1 Overview

The Precision Biomarker Intelligence Agent follows a modular architecture comprising five layers:

1. **Data Layer.** Fourteen Milvus vector collections containing biomarker reference data, genetic variants, pharmacogenomic rules, disease trajectories, clinical evidence, nutrition guidelines, drug interactions, aging markers, genotype adjustments, monitoring protocols, critical values, discordance rules, Ashkenazi Jewish carrier screening data, and shared genomic evidence. Eighteen reference JSON data files in `data/reference/` provide seed data for collection initialization:

   `biomarker_reference.json`, `biomarker_genetic_variants.json`, `biomarker_pgx_rules.json`, `biomarker_disease_trajectories.json`, `biomarker_clinical_evidence.json`, `biomarker_nutrition.json`, `biomarker_drug_interactions.json`, `biomarker_aging_markers.json`, `biomarker_genotype_adjustments.json`, `biomarker_monitoring.json`, `biomarker_critical_values.json`, `biomarker_discordance_rules.json`, `biomarker_aj_carrier_screening.json`, `biomarker_genomic_evidence.json`, `biomarker_lab_ranges.json`, `biomarker_longitudinal_tracking.json`, `biomarker_sample_patients.json`, and `nutrition_guidelines_seed.json`.

2. **Computation Layer.** Four deterministic analysis modules -- BiologicalAgeCalculator, DiseaseTrajectoryAnalyzer, PharmacogenomicMapper, and GenotypeAdjuster -- plus CriticalValueEngine, DiscordanceDetector, and LabRangeInterpreter. These modules perform pure computation with no LLM or database calls, ensuring reproducibility and auditability.

3. **RAG Layer.** The BiomarkerRAGEngine orchestrates parallel vector search across all 14 collections, merges and ranks results with configurable weighted scoring, augments with knowledge graph context, and synthesizes evidence through Claude for grounded response generation.

4. **Agent Layer.** The PrecisionBiomarkerAgent implements the plan-analyze-search-synthesize-report pattern, coordinating all modules and the RAG engine to answer complex cross-functional queries about precision biomarker interpretation.

5. **Interface Layer.** An 8-tab Streamlit UI (port 8528) for interactive exploration and a FastAPI REST API (port 8529) with 19+ endpoints across 3 routers (analysis, reports, events) for programmatic access.

### 3.2 The 14-Collection Architecture

The system maintains 13 biomarker-specific Milvus collections plus one read-only shared genomic evidence collection:

| # | Collection Name | Description | Weight |
|---|----------------|-------------|--------|
| 1 | `biomarker_reference` | Reference biomarker definitions, units, and standard ranges | 0.12 |
| 2 | `biomarker_genetic_variants` | Genetic variants affecting biomarker levels | 0.11 |
| 3 | `biomarker_pgx_rules` | Pharmacogenomic dosing rules following CPIC guidelines | 0.10 |
| 4 | `biomarker_disease_trajectories` | Disease progression trajectory models | 0.10 |
| 5 | `biomarker_clinical_evidence` | Published clinical evidence with PubMed citations | 0.09 |
| 6 | `biomarker_drug_interactions` | Gene-drug interaction records | 0.07 |
| 7 | `biomarker_aging_markers` | Epigenetic aging clock marker data | 0.07 |
| 8 | `biomarker_nutrition` | Genotype-aware nutrition guidelines | 0.05 |
| 9 | `biomarker_genotype_adjustments` | Genotype-based reference range adjustments | 0.05 |
| 10 | `biomarker_monitoring` | Condition-specific monitoring protocols | 0.05 |
| 11 | `biomarker_critical_values` | Critical/panic value thresholds with escalation rules | 0.04 |
| 12 | `biomarker_discordance_rules` | Cross-biomarker discordance detection patterns | 0.04 |
| 13 | `biomarker_aj_carrier_screening` | Ashkenazi Jewish carrier screening genetic data | 0.03 |
| 14 | `genomic_evidence` | Shared genomic variants from VCF pipeline (read-only) | 0.08 |

Collection weights sum to 1.00 and are configurable via environment variables with the `BIOMARKER_` prefix. The weights reflect clinical priority: biomarker reference and genetic variant data receive the highest weights as they are relevant to virtually every query, while specialized collections like AJ carrier screening receive lower weights to avoid diluting general queries with population-specific data.

### 3.3 Embedding Strategy

All collections use BAAI/bge-small-en-v1.5 embeddings (384 dimensions) with cosine similarity and IVF_FLAT indexing. This model was selected for three reasons:

1. **Biomedical performance.** BGE-small-en-v1.5 ranks competitively on biomedical retrieval benchmarks despite its compact size, outperforming models twice its parameter count on domain-specific tasks.

2. **Memory efficiency.** At 384 dimensions, vectors consume approximately 1.5 KB each (384 x 4 bytes), enabling storage of millions of vectors in the DGX Spark's 128 GB unified memory alongside all other system components.

3. **Inference speed.** Embedding generation completes in under 10 ms per query on CPU, with batch processing at 32 documents per batch for collection seeding.

Query embedding uses the BGE instruction prefix: "Represent this sentence for searching relevant passages: " prepended to all query text, following the model's training protocol for asymmetric retrieval.

### 3.4 Parallel Search and Weighted Scoring

The RAG engine searches all 14 collections simultaneously using Python's ThreadPoolExecutor, delegating parallel execution to the BiomarkerCollectionManager's `search_all()` method. Each collection returns up to 5 results (configurable via `TOP_K_PER_COLLECTION`) filtered by a minimum cosine similarity score of 0.4 (`SCORE_THRESHOLD`). Results are then weighted by collection priority using the formula `weighted_score = min(raw_score * (1 + weight), 1.0)`, deduplicated by both record ID and text content (first 200 characters), and ranked by weighted score descending. The top 30 results are retained for LLM prompt construction, with a maximum of 5 evidence items per collection included in the final prompt to prevent context window overflow.

Citation relevance scoring classifies each result as high (score >= 0.75), medium (score >= 0.60), or low relevance, enabling the LLM to prioritize the most semantically relevant evidence in its response. Clinical evidence records with PubMed identifiers are rendered as clickable citations linking directly to the PubMed entry.

Disease-area filtering is applied to collections that include a `disease_area` field (genetic variants, disease trajectories, clinical evidence), automatically detecting the disease domain from the query text using keyword matching across 6 domains (diabetes, cardiovascular, liver, thyroid, iron, nutritional) and restricting search to relevant records. Filter expressions are sanitized against injection via a safe-character regex (`^[A-Za-z0-9 _\-]+$`) with a 50-character length limit. Temporal filtering supports year-range constraints on clinical evidence.

### 3.5 Knowledge Graph Augmentation

Beyond vector retrieval, the RAG engine augments search results with structured context from a multi-domain knowledge graph. The knowledge module (`src/knowledge.py`) contains four knowledge bases:

1. **BIOMARKER_DOMAINS (7 domains).** Disease domains (diabetes, cardiovascular, liver, thyroid, iron, nutritional, metabolic) with associated biomarkers, genetic modifiers, clinical thresholds, and intervention targets.

2. **PHENOAGE_KNOWLEDGE.** PhenoAge clock biomarker descriptions, coefficients, clinical interpretation guidelines, and actionable aging drivers.

3. **PGX_KNOWLEDGE (14 pharmacogenes).** Key drug interactions, CPIC guidance summaries, and clinical impact descriptions for each supported pharmacogene.

4. **CROSS_MODAL_LINKS (8 links).** Mappings from biomarker findings to triggers for other HCLS AI Factory agents (imaging, oncology, genomics pipeline), enabling automatic cross-modal escalation.

The knowledge graph is queried by analyzing the user's question for domain keywords, pharmacogene mentions, biomarker names, and aging-related terms. Matching context is injected into the LLM prompt alongside vector-retrieved evidence, providing structured clinical context that pure semantic search may not surface.

### 3.6 System Prompt Engineering

The RAG engine employs a domain-expert system prompt spanning 9 areas of biomarker expertise: biological aging, pre-symptomatic disease detection, pharmacogenomic drug-gene interactions, genotype-adjusted reference ranges, nutritional genomics, cardiovascular risk stratification, liver health assessment, iron metabolism, and Ashkenazi Jewish carrier screening. The prompt instructs the LLM to cite evidence using collection labels, specify units for all biomarker values, provide genotype-specific interpretation when patient data is available, highlight critical findings prominently, and acknowledge uncertainty where appropriate.

---

## 4. Pharmacogenomics Engine

### 4.1 Architecture

The PharmacogenomicMapper is a deterministic computation module that translates star allele diplotypes into metabolizer phenotypes and drug dosing recommendations following CPIC Level 1A guidelines. The module operates without LLM or database calls, ensuring reproducible and auditable results.

### 4.2 Supported Pharmacogenes

The engine supports 14 primary pharmacogenes with full CPIC guideline mapping:

| Gene | CPIC Version | Key Drug Classes | Clinical Impact |
|------|-------------|-----------------|-----------------|
| CYP2D6 | 2019 (updated 2020-12) | Opioids, SSRIs, tamoxifen, antipsychotics | Pain management, psychiatry, oncology |
| CYP2C19 | 2022 (updated 2022-12) | Clopidogrel, PPIs, voriconazole, SSRIs | Cardiology, gastroenterology, psychiatry |
| CYP2C9 | 2017 (updated 2020-01) | Warfarin, NSAIDs, phenytoin | Anticoagulation, pain, neurology |
| CYP3A5 | 2015 (updated 2022-11) | Tacrolimus, cyclosporine | Transplant immunosuppression |
| SLCO1B1 | 2022 (updated 2022-06) | Statins (simvastatin, atorvastatin) | Cardiovascular, myopathy risk |
| VKORC1 | 2017 (updated 2020-01) | Warfarin | Anticoagulation dose adjustment |
| MTHFR | Informational | Methotrexate, folate metabolism | Methylation, cardiovascular risk |
| TPMT | 2018 (updated 2023-03) | Azathioprine, 6-mercaptopurine | Immunosuppression, oncology |
| DPYD | 2017 (updated 2023-12) | Fluoropyrimidines (5-FU, capecitabine) | Oncology, toxicity prevention |

Additional pharmacogenes supported at informational level include HLA-B\*57:01 (abacavir hypersensitivity), HLA-B\*58:01 (allopurinol hypersensitivity), G6PD (oxidative drug hemolysis), UGT1A1 (irinotecan toxicity), and NUDT15 (thiopurine toxicity).

### 4.3 Star Allele to Metabolizer Phenotype Mapping

The engine implements a two-step mapping process:

**Step 1: Activity Score Calculation.** Each star allele is assigned a functional activity score. For CYP2D6, common assignments include: \*1 (normal function, score 1.0), \*2 (normal function, score 1.0), \*4 (no function, score 0.0), \*5 (gene deletion, score 0.0), \*10 (decreased function, score 0.5), \*17 (decreased function, score 0.5), \*41 (decreased function, score 0.5). The diplotype activity score is the sum of both allele scores.

**Step 2: Phenotype Classification.** Activity score ranges map to standardized metabolizer phenotypes: poor metabolizer (score 0), intermediate metabolizer (score 0.5-1.0), normal metabolizer (score 1.5-2.0), and ultrarapid metabolizer (score > 2.0, including gene duplications denoted by xN notation).

### 4.4 Drug Dosing Recommendations

Each metabolizer phenotype maps to CPIC-recommended dosing adjustments. For example, a CYP2D6 poor metabolizer receiving codeine receives the recommendation: "Avoid codeine. Use alternative analgesic not metabolized by CYP2D6 (morphine, oxycodone with caution, non-opioid alternatives). Codeine is a prodrug requiring CYP2D6 conversion to morphine; poor metabolizers will experience no analgesic effect." Conversely, a CYP2D6 ultrarapid metabolizer receives: "Avoid codeine. Risk of life-threatening respiratory depression due to rapid conversion to morphine. Use alternative analgesic."

Additional clinically significant examples include:

- **CYP2C19 poor metabolizer + clopidogrel:** Recommend alternative antiplatelet agent (prasugrel, ticagrelor). Poor metabolizers cannot convert clopidogrel to its active metabolite, resulting in inadequate platelet inhibition and increased cardiovascular event risk.
- **SLCO1B1 decreased function + simvastatin:** Recommend reduced dose or alternative statin. SLCO1B1 variants impair hepatic uptake of simvastatin, increasing systemic exposure and myopathy risk.
- **DPYD poor metabolizer + fluoropyrimidines:** Contraindicated. DPYD deficiency causes severe, potentially fatal toxicity with 5-fluorouracil and capecitabine. This is one of the most safety-critical pharmacogenomic interactions.
- **VKORC1 + CYP2C9 + warfarin:** The system integrates both gene contributions to recommend warfarin dose adjustments, as VKORC1 determines sensitivity while CYP2C9 determines metabolism rate.

---

## 5. Biological Age Estimation

### 5.1 PhenoAge Implementation

The BiologicalAgeCalculator implements the PhenoAge algorithm (Levine et al. 2018, PMID:29676998) using coefficients from the dayoonkwon/BioAge R package. PhenoAge estimates biological age from 9 routine clinical biomarkers:

| Biomarker | Coefficient | Direction | Input Unit | SI Unit |
|-----------|------------|-----------|------------|---------|
| Albumin | -0.0336 | Protective | g/dL | g/L |
| Creatinine | 0.0095 | Aging | mg/dL | umol/L |
| Glucose | 0.1953 | Aging | mg/dL | mmol/L |
| ln(CRP) | 0.0954 | Aging | mg/L | ln(mg/L) |
| Lymphocyte % | -0.0120 | Protective | % | % |
| MCV | 0.0268 | Aging | fL | fL |
| RDW | 0.3306 | Aging | % | % |
| Alkaline Phosphatase | 0.0019 | Aging | U/L | U/L |
| WBC | 0.0554 | Aging | 10^3/uL | 10^3/uL |

The implementation accepts standard US clinical units (g/dL, mg/dL) and converts internally to SI units before applying coefficients, using validated conversion factors: albumin x10 (g/dL to g/L), creatinine x88.4 (mg/dL to umol/L), glucose /18.016 (mg/dL to mmol/L). A chronological age coefficient of 0.0804 is added to the linear predictor, which is then transformed through a Gompertz mortality model to yield a mortality score. The mortality score is converted to biological age using parameters from the age-only Gompertz model (intercept 141.50225, age coefficient 0.09165).

Age acceleration is defined as biological age minus chronological age. The system classifies mortality risk as HIGH (acceleration > 5 years), MODERATE (> 2 years), NORMAL (-2 to +2 years), or LOW (< -2 years, indicating decelerated aging). Each result includes 95% confidence intervals based on published standard error (4.9 years for the full 9-biomarker model, 6.5 years when biomarkers are missing), per-biomarker contribution analysis sorted by absolute magnitude, and a confidence qualifier (high/moderate/low) based on data completeness.

### 5.2 GrimAge Surrogate Estimation

The GrimAge surrogate module estimates GrimAge acceleration from plasma protein markers that correlate with DNAm GrimAge components. Six plasma proteins are evaluated: GDF-15 (weight 0.15), cystatin C (weight 0.12), adrenomedullin (weight 0.11), PAI-1 (weight 0.10), TIMP-1 (weight 0.09), and leptin (weight 0.08). Each marker's deviation from its reference upper bound is weighted and scaled to approximate years of age acceleration.

The surrogate approach has important limitations, which the system explicitly communicates: true GrimAge requires DNA methylation data and includes smoking pack-years as a major component not captured by plasma surrogates. Validation against the Lothian Birth Cohort 1936 (n=906) shows the surrogate correlation with true GrimAge is r-squared = 0.72 (Hillary et al. 2020, PMID:32941527), with a standard error of 5.8 years. The system reports a confidence score scaled by both the base correlation and marker coverage, ensuring that incomplete marker panels yield appropriately cautious estimates.

---

## 6. Disease Trajectory Prediction

### 6.1 Architecture

The DiseaseTrajectoryAnalyzer detects pre-symptomatic disease trajectories across 9 disease categories using genotype-stratified biomarker thresholds. The module is deterministic -- no LLM or database calls -- enabling reproducible stage classification and risk scoring.

### 6.2 Disease Categories

| Category | Key Biomarkers | Genetic Modifiers | Stages |
|----------|---------------|-------------------|--------|
| Type 2 Diabetes | HbA1c, fasting glucose, insulin, HOMA-IR | TCF7L2, PPARG, SLC30A8, KCNJ11, GCKR | Normal, early metabolic shift, insulin resistance, pre-diabetic, diabetic |
| Cardiovascular | Lp(a), LDL-C, ApoB, hs-CRP, total cholesterol, HDL-C, triglycerides | APOE, PCSK9, LPA, LDLR | Normal, borderline risk, moderate risk, high risk, very high risk |
| Liver (NAFLD/NASH) | ALT, AST, GGT, FIB-4 index, platelets | PNPLA3, TM6SF2, HSD17B13 | Normal, simple steatosis, NASH, fibrosis, cirrhosis |
| Kidney | eGFR, creatinine, BUN, albumin-creatinine ratio | APOL1, UMOD, PKD1 | Normal, mild reduction, moderate, severe, kidney failure |
| Thyroid | TSH, free T4, free T3, TPO antibodies | DIO2, FOXE1, TSHR | Normal, subclinical hypothyroid, overt hypothyroid, subclinical hyperthyroid, overt hyperthyroid |
| Iron Metabolism | Ferritin, transferrin saturation, serum iron | HFE C282Y, HFE H63D | Normal, iron deficiency, iron overload, anemia, polycythemia |
| Nutritional | Omega-3, Vit D, B12, folate, Mg, Zn | FADS1, FADS2, VDR, BCMO1, FUT2 | Normal, mild deficiency, moderate deficiency, severe deficiency, multi-nutrient |
| Cognitive | Homocysteine, B12, folate, hs-CRP | APOE, MTHFR | Normal, early cognitive shift, mild impairment, moderate impairment, severe |
| Bone Health | Calcium, PTH, vitamin D, CTX, P1NP, phosphorus | VDR, COL1A1, ESR1 | Normal, vitamin D insufficiency, osteopenia risk, osteoporosis risk, metabolic bone disease |

### 6.3 Genotype-Stratified Thresholds

The trajectory engine adjusts detection thresholds based on individual genotype. For example, the HbA1c threshold for "early metabolic shift" detection is:

- TCF7L2 wild-type (CC): 6.0%
- TCF7L2 heterozygous (CT): 5.8%
- TCF7L2 homozygous risk (TT): 5.5%

Similarly, PNPLA3 genotype adjusts the ALT upper reference limit: CC carriers use 56 U/L, CG carriers use 45 U/L, and GG carriers (I148M homozygous) use 35 U/L. These genotype-specific thresholds are derived from published genetic epidemiology studies and enable earlier detection of disease progression in genetically predisposed individuals.

### 6.4 Stage Classification and Risk Scoring

Each disease category defines ordered stages from normal to severe. The analyzer evaluates all available biomarkers for each category, applies genotype-specific threshold adjustments where applicable, and classifies the patient into the highest triggered stage. Risk scores are computed as weighted sums of biomarker deviations from genotype-adjusted thresholds, normalized to a 0-1 scale.

### 6.5 Clinical Significance of Pre-Symptomatic Detection

The clinical value of genotype-stratified trajectory analysis lies in the detection window it creates between early metabolic deviation and conventional clinical diagnosis. For type 2 diabetes, population-based screening identifies prediabetes at HbA1c 5.7-6.4% (ADA 2024 Standards of Care). A TCF7L2 TT carrier, however, may benefit from lifestyle intervention at HbA1c 5.5% -- a threshold that is "normal" by conventional criteria but represents the beginning of beta-cell deterioration in this genetic context. This earlier detection window, typically 2-5 years before conventional diagnostic thresholds are crossed, aligns with the evidence for lifestyle intervention efficacy in the Diabetes Prevention Program, where carriers of TCF7L2 risk alleles showed the greatest benefit from intensive lifestyle modification (Florez et al. 2012).

Similarly, for liver disease, a PNPLA3 GG carrier with an ALT of 38 U/L would be classified as "normal" by standard reference ranges (upper limit 56 U/L for males) but as potentially steatotic by the genotype-adjusted threshold of 35 U/L. Early identification enables intervention with dietary modification, exercise, and hepatology referral before progression to NASH or fibrosis -- a critical distinction given the limited therapeutic options available once advanced fibrosis is established.

---

## 7. Genotype-Based Reference Ranges

### 7.1 The Case for Individualized Reference Ranges

Standard reference ranges are derived from population distributions, typically the central 2.5th to 97.5th percentile of a healthy reference cohort. While statistically sound, this approach assumes biochemical homogeneity within the reference population -- an assumption invalidated by decades of pharmacogenomic and genetic epidemiology research.

The GenotypeAdjuster module replaces population averages with genotype-stratified reference ranges for biomarkers where genetic variation has a clinically validated impact on normal values. The adjustments are drawn from published literature with specific PubMed identifiers and are applied as modifications to the standard reference range.

### 7.2 Supported Genotype Adjustments

Key genotype-biomarker adjustment pairs include:

- **MTHFR C677T (rs1801133):** Adjusts homocysteine upper reference limit from 15 umol/L (CC) to 12 umol/L (CT) to 10 umol/L (TT). Source: Frosst et al. 1995, PMID:7647779.
- **APOE genotype:** Adjusts LDL-C and total cholesterol targets. E4 carriers have elevated baseline LDL and may require more aggressive statin therapy.
- **PNPLA3 I148M (rs738409):** Adjusts ALT upper reference limit from 56 U/L (CC) to 45 U/L (CG) to 35 U/L (GG). Source: Romeo et al. 2008, PMID:18820127; Sookoian & Pirola 2011, PMID:21520172.
- **DIO2 Thr92Ala (rs225014):** Adjusts TSH upper reference limit from 4.0 mIU/L (GG) to 3.5 mIU/L (GA) to 3.0 mIU/L (AA). Source: Panicker et al. 2009, PMID:19820026; Castagna et al. 2017, PMID:28100792.
- **HFE C282Y/H63D:** Adjusts ferritin and transferrin saturation thresholds for hereditary hemochromatosis carriers.
- **VDR variants:** Adjusts vitamin D (25-OH) sufficiency thresholds based on VDR receptor efficiency.
- **FADS1 variants:** Adjusts omega-3 index interpretation based on desaturase enzyme efficiency.

### 7.3 Ancestry-Aware Adjustments

Beyond single-gene adjustments, the system applies ancestry-aware reference range modifications informed by large-scale population studies including NHANES III, UK Biobank, and MESA. These adjustments account for population-level differences in biomarker distributions that reflect both genetic ancestry and environmental factors. Age- and sex-stratified reference ranges are further layered using clinically validated brackets (0-17, 18-39, 40-59, 60-79, 80+) with sources including KDIGO 2012, ATA 2017, ADA 2024, and ACC/AHA 2019 guidelines.

### 7.4 Ashkenazi Jewish Carrier Screening

The system includes a dedicated AJ carrier screening collection covering a 10-gene panel: BRCA1/2, GBA, HEXA, FANCC, ASPA, BLM, SMPD1, IKBKAP/ELP1, and MCOLN1. This module provides reproductive counseling context, compound risk analysis (e.g., GBA carrier status combined with APOE E4 for Parkinson's disease risk), and population-specific carrier frequency data. Both demo patients in the system are of Ashkenazi Jewish ancestry, reflecting the clinical importance of ancestral context in biomarker interpretation.

---

## 8. Clinical Intelligence Features

### 8.1 Critical Value Detection

The CriticalValueEngine evaluates patient biomarker values against critical/panic value thresholds in real time. Thresholds are loaded from `biomarker_critical_values.json` and classified by severity (critical, urgent, warning). Each triggered alert includes the biomarker name and value, threshold and direction (high/low), escalation target (e.g., attending physician, nephrologist), recommended clinical action, cross-check biomarkers for confirmation, and LOINC code for interoperability.

### 8.2 Cross-Biomarker Discordance Detection

The DiscordanceDetector evaluates pairs of biomarker values against known discordance patterns loaded from `biomarker_discordance_rules.json`. A discordance finding represents a clinically unexpected or contradictory relationship between two biomarkers -- for example, elevated ferritin with low transferrin saturation (suggesting inflammation rather than iron overload) or elevated TSH with normal free T4 (suggesting subclinical hypothyroidism vs. assay interference). Each finding includes differential diagnosis suggestions and cross-agent handoff recommendations (e.g., triggering an imaging agent query for hepatic assessment).

### 8.3 Longitudinal Biomarker Tracking

The system supports longitudinal tracking of biomarker values across multiple visits, enabling trend analysis, rate-of-change calculations, and trajectory visualization. The Streamlit UI includes a dedicated Longitudinal tab with interactive time-series charts. Trend analysis is contextualized by genotype: a rising HbA1c trend in a TCF7L2 TT carrier triggers earlier alerts than the same trend in a non-carrier.

### 8.4 Drug Interaction Awareness

The `biomarker_drug_interactions` collection stores gene-drug interaction records that are surfaced during patient analysis. When a patient's pharmacogenomic profile indicates altered metabolism for a drug class, the system flags relevant interactions and provides CPIC-guided dosing adjustments. Cross-modal event triggers can alert the prescribing clinician when biomarker results suggest drug efficacy or toxicity concerns.

### 8.5 Nutritional Genomics

The `biomarker_nutrition` collection provides genotype-aware nutrition guidelines covering:

- MTHFR C677T: methylfolate supplementation recommendations
- FADS1 variants: omega-3 conversion efficiency and supplementation guidance
- VDR variants: vitamin D dosing optimization
- BCMO1 variants: beta-carotene to retinol conversion efficiency
- FUT2 variants: vitamin B12 absorption capacity

---

## 9. Evidence Quality and Export

### 9.1 Citation and Provenance Tracking

Every evidence item retrieved from the vector collections carries provenance metadata including collection label, record ID, cosine similarity score, and relevance classification (high/medium/low). Clinical evidence records include PubMed IDs rendered as clickable citations (e.g., `[ClinicalEvidence:PMID 29676998](https://pubmed.ncbi.nlm.nih.gov/29676998/)`). CPIC guideline versions are tracked per pharmacogene with publication year, PMID, last update date, and evidence level.

### 9.2 Report Generation

The ReportGenerator produces structured 12-section clinical reports:

1. **Biological Age Assessment** -- PhenoAge and GrimAge results with confidence intervals
2. **Executive Findings** -- Top 5 critical/high priority findings
3. **Biomarker-Gene Correlation Map** -- Genotype-biomarker interaction summary
4. **Disease Trajectory Analysis** -- All 9 disease categories with staging
5. **Pharmacogenomic Profile** -- Star alleles, phenotypes, and drug recommendations
6. **Nutritional Analysis** -- Genotype-aware nutritional guidance
7. **Interconnected Pathways** -- Cross-domain pathway connections
8. **Prioritized Action Plan** -- Ranked clinical recommendations
9. **Monitoring Schedule** -- Condition-specific monitoring protocols
10. **Supplement Protocol Summary** -- Evidence-based supplement recommendations
11. **Clinical Summary for MD** -- Concise physician-facing summary
12. **References** -- Complete citation list with PMIDs

### 9.3 Export Formats

The system supports five export formats via public functions in `src/export.py`:

- **Markdown** (`export_markdown()`) -- Human-readable report with evidence tables, formatted citations, and query metadata. Includes filter documentation and timestamp provenance.
- **JSON** (`export_json()`) -- Machine-readable structured data for downstream system integration, preserving all analysis results, evidence scores, and metadata.
- **PDF** (`export_pdf()`) -- Styled clinical report generated via ReportLab Platypus with headers, tables, formatted text, and professional layout suitable for clinical documentation.
- **CSV** (`export_csv()`) -- Tabular export for spreadsheet analysis of biomarker values, reference ranges, risk scores, and trajectory stages.
- **FHIR R4** (`export_fhir_diagnostic_report()`) -- HL7 FHIR R4 DiagnosticReport JSON bundle for electronic health record integration, including patient reference, result observations, coded findings (LOINC where available), and conclusion narrative. This format enables interoperability with EHR systems that support FHIR R4 resource ingestion.

All export functions generate timestamped filenames with UUID suffixes (e.g., `biomarker_report_20260301T143025Z_a1b2.md`) to prevent filename collisions in production environments. The report generation and PDF download endpoints are accessible through both the REST API (`/v1/report/generate`, `/v1/report/{id}/pdf`, `/v1/report/fhir`) and the Streamlit UI Reports tab.

---

## 10. Hardware Democratization

### 10.1 The DGX Spark Platform

The entire Precision Biomarker Intelligence Agent stack -- Milvus vector database (with etcd and MinIO), embedding model, application server, and Streamlit UI -- runs on a single NVIDIA DGX Spark priced at $4,699. The DGX Spark features:

- **GPU:** GB10 (NVIDIA Blackwell architecture)
- **Memory:** 128 GB unified LPDDR5x (shared between CPU and GPU)
- **CPU:** 20 ARM cores (NVIDIA Grace architecture)
- **Storage:** NVMe SSD with sufficient capacity for all vector collections and reference data

This represents a significant departure from traditional biomedical AI deployments that require enterprise GPU servers costing $30,000-$200,000 or recurring cloud compute expenses. The unified memory architecture is particularly advantageous for the multi-collection RAG pattern: all 14 Milvus collections, their IVF_FLAT indices, and the BGE-small-en-v1.5 embedding model can reside in memory simultaneously, eliminating the latency penalties of disk-based index loading.

### 10.2 No Cloud Dependency

All computation occurs on-device. No patient biomarker data, genotype information, or clinical queries leave the device (the sole external call is to the Anthropic API for LLM synthesis, which processes de-identified evidence context rather than raw patient data). This architecture supports deployment in HIPAA- and GDPR-regulated environments where cloud-based processing of protected health information faces compliance barriers.

### 10.3 Deployment Configuration

The system deploys via Docker Compose (`docker-compose.yml`) with the following services:

- Milvus standalone (port 19530) with etcd and MinIO backends
- FastAPI REST API (port 8529)
- Streamlit UI (port 8528)
- Prometheus metrics endpoint (integrated)

Configuration follows the `BIOMARKER_` environment variable prefix convention, with all settings managed through Pydantic BaseSettings with `.env` file support. The `PrecisionBiomarkerSettings` class validates configuration at startup, including checking that collection search weights sum to approximately 1.0 and that all required paths exist.

### 10.4 Audit Logging

All API operations are recorded through a structured audit logging system (`src/audit.py`) that tracks request timestamps, action types, patient identifiers (where applicable), request parameters, and response summaries. Audit logs support compliance requirements for systems handling clinical data and provide an operational trail for debugging and performance analysis.

---

## 11. Results

### 11.1 Test Coverage

The system includes 709 tests across 18 test files covering all major modules:

| Test File | Scope |
|-----------|-------|
| `test_agent.py` | Agent planning, analysis orchestration |
| `test_api.py` | FastAPI endpoint validation |
| `test_biological_age.py` | PhenoAge and GrimAge calculations |
| `test_collections.py` | Milvus collection management |
| `test_critical_values.py` | Critical value detection |
| `test_discordance_detector.py` | Cross-biomarker discordance |
| `test_disease_trajectory.py` | Disease trajectory staging |
| `test_edge_cases.py` | Boundary conditions and error handling |
| `test_export.py` | Markdown, PDF, FHIR R4 export |
| `test_genotype_adjustment.py` | Genotype-based range adjustments |
| `test_integration.py` | End-to-end integration scenarios |
| `test_lab_range_interpreter.py` | Lab range interpretation |
| `test_longitudinal.py` | Longitudinal tracking |
| `test_models.py` | Pydantic model validation |
| `test_pharmacogenomics.py` | Star allele to phenotype mapping |
| `test_rag_engine.py` | RAG retrieval and synthesis |
| `test_report_generator.py` | 12-section report generation |
| `test_ui.py` | Streamlit UI rendering |

### 11.2 Demo Patients

Two demonstration patients validate the system across the full analysis pipeline:

**Patient HG002 (45M, Ashkenazi Jewish).** The Genome in a Bottle HG002 reference sample, a 45-year-old male of Ashkenazi Jewish ancestry. This patient provides a rich genotype profile including CYP2D6, CYP2C19, MTHFR, APOE, and PNPLA3 variants, along with a comprehensive biomarker panel spanning metabolic, hepatic, renal, thyroid, hematologic, and inflammatory domains. HG002 serves as the primary integration test case, demonstrating how genetic variants discovered in the genomics pipeline flow through the biomarker agent to modify reference range interpretation. This is the same reference genome used throughout the HCLS AI Factory's 3-stage pipeline, providing continuity from FASTQ processing through variant calling to biomarker interpretation.

**Patient AJ-F38 (38F, Ashkenazi Jewish).** A 38-year-old female of Ashkenazi Jewish ancestry with a biomarker profile designed to demonstrate reproductive health considerations, carrier screening relevance, and sex-specific reference range adjustments. This patient's profile includes BRCA1/2 and GBA carrier screening results relevant to the AJ carrier screening module. The patient demonstrates age-stratified reference range differences (18-39 bracket), female-specific ferritin and creatinine ranges, and reproductive hormone interpretation with genetic context.

Together, these two patients exercise the full scope of the system: both sexes, two age brackets (18-39 and 40-59), AJ carrier screening, pharmacogenomic profiling, biological age estimation, disease trajectory analysis across all 9 categories, and cross-modal event triggering.

### 11.3 API Surface

The FastAPI REST API exposes 19+ endpoints across 3 routers:

**Analysis Router (`/v1`)**
- `POST /v1/analyze` -- Full patient analysis (all modules)
- `POST /v1/biological-age` -- Biological age calculation
- `POST /v1/disease-risk` -- Disease trajectory analysis
- `POST /v1/pgx` -- Pharmacogenomic mapping
- `POST /v1/query` -- RAG Q&A query
- `POST /v1/query/stream` -- Streaming RAG Q&A with Server-Sent Events
- `GET /v1/health` -- Versioned health check

**Reports Router (`/v1/report`)**
- `POST /v1/report/generate` -- Generate 12-section patient report
- `GET /v1/report/{report_id}/pdf` -- Download report as PDF
- `POST /v1/report/fhir` -- Export as FHIR R4 DiagnosticReport

**Events Router (`/v1/events`)**
- `POST /v1/events/cross-modal` -- Create cross-modal event trigger
- `POST /v1/events/biomarker-alert` -- Create biomarker alert event
- `GET /v1/events/cross-modal` -- List cross-modal events
- `GET /v1/events/biomarker-alert` -- List biomarker alerts

**Root Endpoints**
- `GET /health` -- Service health with collection and vector counts
- `GET /collections` -- Collection names and record counts
- `GET /knowledge/stats` -- Knowledge graph statistics
- `GET /metrics` -- Prometheus-compatible metrics

All endpoints use Pydantic request/response schemas with validation. The API enforces CORS with configurable origins, optional API key authentication, and request size limits (10 MB default).

### 11.4 Query Performance

The parallel multi-collection search architecture achieves sub-second retrieval across all 14 collections on the DGX Spark hardware. Full patient analysis -- encompassing biological age calculation, disease trajectory analysis across 9 categories, pharmacogenomic mapping, genotype adjustment, critical value detection, and discordance analysis -- completes within the configured request timeout of 60 seconds, with typical execution times well under 30 seconds. LLM synthesis via Claude adds variable latency depending on response complexity, typically 5-15 seconds for standard queries.

### 11.5 User Interface

The 8-tab Streamlit UI provides interactive access to all agent capabilities:

| Tab | Function |
|-----|----------|
| Biomarker Analysis | Full patient analysis pipeline with sample patient quick-load |
| Biological Age | Interactive PhenoAge calculator with contribution visualization |
| Disease Risk | Focused disease trajectory analysis across 9 categories |
| PGx Profile | Pharmacogenomic drug interaction mapping |
| Evidence Explorer | RAG Q&A with collection filtering and evidence scoring |
| Reports | PDF and FHIR R4 report generation and download |
| Patient 360 | Unified cross-agent intelligence dashboard |
| Longitudinal | Biomarker trend tracking across multiple visits |

---

## 12. Integration with HCLS AI Factory

### 12.1 Three-Stage Pipeline Context

The Precision Biomarker Intelligence Agent operates as one of five intelligence agents within the HCLS AI Factory, an end-to-end precision medicine platform that processes patient DNA from raw FASTQ files to drug candidates in under 5 hours. The three-stage pipeline comprises:

1. **Genomics Pipeline.** Parabricks 4.6 (GPU-accelerated DeepVariant + BWA-MEM2) process raw sequencing data (FASTQ) into annotated variant calls (VCF), achieving 120-240 minute genome processing on GPU versus 24-48 hours on CPU.

2. **RAG/Chat Pipeline.** Milvus vector database with 3.56 million searchable vectors across 4.1 million ClinVar records and 71 million AlphaMissense predictions, powered by Claude for variant interpretation.

3. **Drug Discovery Pipeline.** BioNeMo MolMIM, DiffDock, and RDKit generate and evaluate drug candidates against identified therapeutic targets.

### 12.2 The Genomic Evidence Bridge

The `genomic_evidence` collection (collection #14) serves as a read-only bridge between the genomics pipeline and the biomarker agent. Variants identified during genome analysis -- annotated with ClinVar pathogenicity classifications, allele frequencies, and functional predictions -- are accessible to the biomarker agent without duplication. This enables queries such as "What are the implications of this patient's HFE C282Y homozygous genotype for their ferritin levels?" to retrieve both the genomic evidence (variant pathogenicity, population frequency) and the biomarker interpretation (adjusted ferritin reference range, hereditary hemochromatosis monitoring protocol).

### 12.3 Cross-Modal Event Triggers

The biomarker agent generates cross-modal event triggers when analysis findings warrant follow-up by other HCLS AI Factory agents. The 8 cross-modal links defined in the knowledge graph include:

- Elevated Lp(a) or ApoB triggering cardiovascular imaging assessment
- Abnormal liver biomarkers in PNPLA3 carriers triggering hepatic imaging
- Pathogenic BRCA1/2 carrier status triggering oncology agent review
- Accelerated biological aging triggering genomic pipeline review for aging-associated variants
- Pharmacogenomic findings triggering drug discovery pipeline for alternative compound identification

These triggers are exposed through the `/v1/events/cross-modal` API endpoint and displayed in the Patient 360 unified dashboard tab.

### 12.4 The 11 HCLS AI Factory Intelligence Agents

The HCLS AI Factory employs a three-engine architecture:

1. **Genomic Foundation Engine** -- GPU-accelerated variant calling (Parabricks/DeepVariant/BWA-MEM2)
2. **Precision Intelligence Network** -- 11 domain-specialized RAG agents providing cross-functional clinical intelligence
3. **Therapeutic Discovery Engine** -- BioNeMo/DiffDock/RDKit for molecular generation, docking, and lead optimization

The biomarker agent operates alongside 10 sibling agents within the Precision Intelligence Network:

| # | Agent | Domain |
|---|-------|--------|
| 1 | Precision Oncology Agent | Molecular tumor board decision support |
| 2 | CAR-T Intelligence Agent | CAR-T cell therapy development lifecycle |
| 3 | **Precision Biomarker Agent** (this agent) | Genotype-aware biomarker interpretation |
| 4 | Clinical Trial Intelligence Agent | Trial landscape monitoring and matching |
| 5 | Cardiology Intelligence Agent | Cardiovascular risk and treatment optimization |
| 6 | Neurology Intelligence Agent | Neurological disease characterization |
| 7 | Pharmacogenomics (PGx) Agent | Drug-gene interaction and dosing guidance |
| 8 | Medical Imaging Intelligence Agent | Imaging AI with NVIDIA NIM microservices |
| 9 | Single-Cell Intelligence Agent | Single-cell omics analysis |
| 10 | Autoimmune Intelligence Agent | Autoimmune disease monitoring and treatment |
| 11 | Rare Disease Intelligence Agent | Rare disease diagnosis and therapeutic matching |

The biomarker agent calls 4 peer agents via `cross_modal/cross_agent.py` and the `/integrated-assessment` endpoint: Oncology, CAR-T, PGx, and Clinical Trial agents.

All agents share the `genomic_evidence` collection as a common data substrate, enabling cross-agent queries and unified patient views through the Patient 360 dashboard. The shared collection architecture ensures that variants identified during genome analysis are immediately available to all agents without data duplication, while each agent maintains its own domain-specific collections for specialized retrieval.

### 12.5 Data Flow Example

A representative end-to-end data flow illustrates the integration:

1. **Genomics Pipeline** processes a patient's whole genome sequencing data, identifying a CYP2D6 \*4/\*4 genotype (poor metabolizer) and an MTHFR C677T TT homozygous variant.
2. Variants are annotated with ClinVar pathogenicity and loaded into the shared `genomic_evidence` collection.
3. The **Biomarker Intelligence Agent** retrieves the patient's genotype from `genomic_evidence`, adjusts the homocysteine reference range (15 to 10 umol/L for MTHFR TT), classifies the CYP2D6 phenotype as poor metabolizer, and flags contraindicated medications.
4. The patient's elevated CRP and accelerated PhenoAge trigger a **cross-modal event** to the Imaging Intelligence Agent for cardiovascular risk assessment.
5. The **Patient 360 dashboard** displays integrated findings across all agents in a unified view.

---

## 13. Pediatric Biomarker Applications

### 13.1 Pediatric ALL Biomarkers

The Precision Biomarker Intelligence Agent supports critical pediatric oncology biomarkers, with particular depth in acute lymphoblastic leukemia (ALL):

- **CD19** -- the primary target antigen for CAR-T therapy in pediatric B-ALL. The biomarker agent tracks CD19 expression levels, detects CD19-low/negative status indicating potential CAR-T resistance, and triggers cross-agent alerts to the CAR-T Intelligence Agent when CD19 loss is identified.
- **CD22** -- the leading alternative target for CD19-negative relapse. CD22 expression quantification informs eligibility for CD22-directed CAR-T or bispecific antibody therapies.
- **CRLF2** -- cytokine receptor-like factor 2 overexpression, found in approximately 5-7% of pediatric B-ALL cases and associated with Philadelphia-like (Ph-like) ALL. CRLF2 overexpression identifies patients who may benefit from JAK inhibitor therapy and stratifies risk within the Ph-like subgroup.

### 13.2 Minimal Residual Disease (MRD) Detection

MRD is the strongest prognostic biomarker in pediatric ALL. The biomarker agent interprets MRD levels from flow cytometry and molecular assays:

- MRD-negative (< 0.01%) at end-of-induction: favorable prognosis, standard-risk therapy
- MRD-positive (>= 0.01%) at end-of-induction: high-risk stratification, consideration for intensified therapy or CAR-T
- MRD conversion after consolidation: critical decision point for transplant versus CAR-T versus continued chemotherapy

The agent generates cross-agent events to the Oncology Agent and CAR-T Agent when MRD status changes clinical risk stratification.

### 13.3 MYCN Amplification in Neuroblastoma

MYCN amplification is a critical prognostic biomarker in pediatric neuroblastoma, present in approximately 20-25% of cases and strongly associated with high-risk disease and poor outcomes. The biomarker agent detects MYCN amplification from genomic data and:

- Classifies patients into high-risk neuroblastoma regardless of age or stage
- Triggers cross-agent alerts to the Oncology Agent for immediate high-risk therapy ranking
- Correlates with other neuroblastoma biomarkers (urinary catecholamines, LDH, ferritin, neuron-specific enolase)
- Monitors for MYCN-driven therapy response biomarkers during treatment

---

## 14. Discussion

### 14.1 Limitations

Several limitations merit acknowledgment:

**Genotype coverage.** The current system supports genotype adjustments for a curated set of well-validated gene-biomarker associations. As pharmacogenomic and GWAS research expands, additional adjustments will need to be incorporated. The modular architecture -- with adjustments defined in data files rather than hardcoded logic -- facilitates this expansion.

**PhenoAge and GrimAge accuracy.** PhenoAge was developed and validated primarily in US populations (NHANES III, InCHIANTI cohort). Its accuracy may vary across populations not well represented in the training data. The GrimAge surrogate using plasma proteins explains approximately 72% of variance in true DNAm GrimAge, and the system explicitly communicates this limitation in every surrogate result.

**Disease trajectory simplification.** The trajectory engine uses threshold-based staging rather than continuous probabilistic models. While thresholds are genotype-stratified and evidence-based, they represent a simplification of the complex, multifactorial processes driving disease progression. Trajectory predictions should be interpreted as risk indicators rather than diagnostic conclusions.

**LLM dependency.** Evidence synthesis relies on Claude via the Anthropic API, introducing an external dependency and potential latency variability. The deterministic computation modules (biological age, trajectories, pharmacogenomics, genotype adjustment, critical values, discordance detection) operate independently of the LLM, but natural language query responses require the API connection.

**Clinical validation.** While individual components (PhenoAge coefficients, CPIC guidelines, genotype-threshold relationships) are drawn from peer-reviewed literature, the integrated system has not undergone prospective clinical validation. The system is designed as a clinical decision support tool, not a diagnostic device, and all outputs include appropriate disclaimers. Validation in diverse clinical settings with real patient outcomes is a prerequisite for any production clinical deployment.

**Reference data currency.** Clinical guidelines and pharmacogenomic recommendations evolve continuously. The system tracks knowledge base version metadata (CPIC guideline versions, ADA standards year, ESC/EAS guidelines year) and includes last-updated timestamps, but maintaining currency requires systematic monitoring of guideline publications and periodic reference data updates.

### 14.2 Future Directions

**Polygenic risk score integration.** Incorporating genome-wide polygenic risk scores for diseases such as coronary artery disease, type 2 diabetes, and breast cancer would enhance trajectory predictions beyond the current common-variant approach.

**Continuous learning.** Implementing feedback loops from clinician interactions -- confirming or correcting biomarker interpretations -- could improve genotype-threshold calibration over time while maintaining the deterministic, auditable nature of the computation modules.

**Multi-omics integration.** Extending beyond genomics and standard blood biomarkers to incorporate proteomics, metabolomics, and methylation data would enable true multi-omics biological age estimation (replacing the current plasma protein surrogate for GrimAge) and more granular disease trajectory modeling.

**Expanded ancestry coverage.** Broadening ancestry-aware reference range adjustments to cover additional population groups, informed by emerging biobank data from diverse global populations, would improve the system's utility across all patient populations.

**Real-time EHR integration.** Developing HL7 FHIR-based interfaces for real-time ingestion of laboratory results from electronic health record systems would enable continuous biomarker monitoring and automated alert generation, moving from retrospective analysis to prospective clinical surveillance.

**On-device LLM inference.** Replacing the external Anthropic API dependency with on-device LLM inference using NVIDIA NIM microservices (e.g., Llama-3 8B or BioMistral) would eliminate the sole cloud dependency, achieving complete data sovereignty for environments where even de-identified evidence context cannot leave the device. The DGX Spark's 128 GB unified memory is sufficient to host a quantized 8B-parameter model alongside all other system components.

**Expanded discordance patterns.** The current discordance detection engine evaluates pairwise biomarker relationships. Extending to multi-biomarker pattern recognition -- identifying clinically significant configurations across three or more biomarkers simultaneously -- would capture complex pathophysiological states that pairwise analysis misses. Machine learning approaches trained on clinical outcome data could complement the current rule-based engine.

**International reference range databases.** Partnering with international laboratory medicine organizations to incorporate region-specific reference ranges would improve the system's global applicability. Current reference ranges are primarily derived from North American and European population studies; broadening this foundation would better serve diverse patient populations worldwide.

---

## 15. Conclusion

The Precision Biomarker Intelligence Agent demonstrates that genotype-aware biomarker interpretation is technically feasible, computationally efficient, and deployable on accessible hardware. By combining multi-collection retrieval-augmented generation with deterministic computational engines for biological aging, disease trajectories, pharmacogenomics, and genotype-adjusted reference ranges, the system transforms the fundamental unit of laboratory medicine -- the reference range -- from a population average into a personalized boundary informed by individual genetic variation.

The 14-collection architecture ensures that biomarker queries are answered with evidence spanning reference data, genetic variants, pharmacogenomic rules, disease trajectories, clinical literature, nutrition guidelines, drug interactions, aging markers, monitoring protocols, critical values, discordance patterns, ancestry-specific screening data, and patient genomic evidence. The four deterministic computation modules provide reproducible, auditable analyses that do not depend on LLM availability, while the RAG engine synthesizes natural language responses grounded in retrieved evidence with full citation provenance.

Running on a single NVIDIA DGX Spark at $4,699, the system places precision biomarker intelligence within the reach of community health systems, research institutions, and clinical laboratories that lack the infrastructure for enterprise-scale deployments. The open-source release under Apache 2.0 removes licensing barriers to adoption, customization, and academic research.

The design philosophy underlying the system -- separating deterministic computation from LLM synthesis -- merits emphasis. The biological age calculator, disease trajectory analyzer, pharmacogenomic mapper, genotype adjuster, critical value engine, discordance detector, and lab range interpreter all operate as pure computational modules with no LLM dependency. They produce reproducible, auditable results from defined inputs using published coefficients and evidence-based thresholds. The LLM serves exclusively as a synthesis and communication layer, translating structured analytical outputs into natural language for clinical consumption. This separation ensures that the clinical core of the system is deterministic and testable, while the communication layer benefits from the flexibility of large language models.

The gap between population-average laboratory medicine and genotype-informed precision health is not primarily a scientific gap -- the evidence for genotype-biomarker interactions is robust and growing. It is an implementation gap: the failure to connect genetic data that increasingly exists in patient records with the laboratory results that clinicians interpret daily. This system represents one approach to closing that gap, translating decades of pharmacogenomic and genetic epidemiology research into a practical tool for individualized biomarker interpretation.

---

## 16. References

1. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. *N Engl J Med*. 2005;352(17):1769-1778. PMID:15858186.

2. Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *eLife*. 2022;11:e73420. PMID:35029144.

3. Castagna MG, Dentice M, Cantara S, et al. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. *J Clin Endocrinol Metab*. 2017;102(5):1623-1630. PMID:28100792.

4. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Genet Med*. 2017;19(2):215-223. PMID:27441996.

5. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N Engl J Med*. 2006;355(3):241-250. PMID:22399527.

6. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet*. 1995;10(1):111-113. PMID:7647779.

7. Grant SFA, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat Genet*. 2006;38(3):320-323. PMID:16415884.

8. Hillary RF, Stevenson AJ, McCartney DL, et al. Epigenetic measures of ageing predict the prevalence and incidence of leading causes of death and disease burden. *Clin Epigenetics*. 2020;12(1):115. PMID:32941527.

9. Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med*. 2021;385(19):1737-1749. PMID:34554658.

10. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging*. 2018;10(4):573-591. PMID:29676998.

11. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging*. 2019;11(2):303-327. PMID:30669119.

12. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31(23):2844-2853. PMID:20965889.

13. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. *J Clin Endocrinol Metab*. 2009;94(5):1623-1629. PMID:19190113.

14. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet*. 2008;40(12):1461-1465. PMID:18820127.

15. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology*. 2011;53(6):1883-1894. PMID:21520172.

16. Tanaka T, Biancotto A, Moaddel R, et al. Plasma proteomic signature of age in healthy humans. *Aging Cell*. 2018;17(5):e12799. PMID:29992731.

17. CPIC Guidelines. Clinical Pharmacogenetics Implementation Consortium. https://cpicpgx.org/guidelines/. Accessed March 2026.

18. HL7 FHIR R4 DiagnosticReport Resource. https://www.hl7.org/fhir/diagnosticreport.html. Accessed March 2026.

---

**Acknowledgments.** This work was developed as part of the HCLS AI Factory platform. PhenoAge coefficients were validated against the dayoonkwon/BioAge R package implementation. CPIC guideline mappings follow published recommendations from cpicpgx.org. The system uses Claude (Anthropic) for evidence synthesis and BAAI/bge-small-en-v1.5 for semantic embeddings.

**Conflicts of Interest.** None declared.

**Data Availability.** All source code, reference data files, and test suites are available in the HCLS AI Factory repository under the Apache 2.0 license. No patient-identifiable data is included; demonstration patients use synthetic biomarker profiles.

**Code Repository.** https://github.com/ajones1923/hcls-ai-factory
